Negative Regulators of Angiogenesis in Inflammatory Bowel Disease: Thrombospondin in the Spotlight | Zendy

Silvio Danese | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Negative Regulators of Angiogenesis in Inflammatory Bowel Disease: Thrombospondin in the Spotlight

Author(s) -

Silvio Danese

Publication year - 2008

Publication title -

pathobiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.941

H-Index - 53

eISSN - 1423-0291

pISSN - 1015-2008

DOI - 10.1159/000113791

Subject(s) - angiogenesis , thrombospondin 1 , inflammation , thrombospondin , inflammatory bowel disease , medicine , immunology , ulcerative colitis , pathological , neovascularization , crohn's disease , cancer research , disease , pathology , matrix metalloproteinase , metalloproteinase

Angiogenesis is the growth of new blood vessels. In the two major forms of inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis, robust angiogenesis exists, and its blockade may have therapeutic potential, as shown in animal models of experimental intestinal inflammation. While abundant literature is available on the positive regulators of intestinal pathological angiogenesis, e.g. VEGF, b-FGF, IL-8, CD40 and CD40L, almost no data exist on negative regulators. Thrombospondin-1 is a negative regulator of angiogenesis, and it plays a new role in IBD-associated angiogenesis. In addition, recombinant thrombospondin-1 may inhibit pathological angiogenesis and may offer a new therapeutic approach to intestinal inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research